• Regeneron's expanded Sanofi alliance includes $1 billion upfront, up to $7 billion in milestones and a 50:50 global profit split.
• Third-quarter 2026 revenue totaled $5.1 billion; non-GAAP diluted earnings reached $20.07 per share.
• Dupixent global net sales rose 35% to $6.5 billion, with more than 1.5 million patients on therapy globally.
• Sanofi collaboration revenue increased 68% to $2.7 billion, reflecting a full share of profits for the first time.
• A Phase 3 trial of fianlimab with cemiplimab missed its primary endpoint against pembrolizumab in first-line metastatic melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.